
Medtronic wins CE mark for VitalFlow ECMO transport tech
Medtronic (NYSE:MDT) announced today that it received CE mark approval for its VitalFlow Transport Frame Air and Ground (AG) accessory.

Medtronic (NYSE:MDT) announced today that it received CE mark approval for its VitalFlow Transport Frame Air and Ground (AG) accessory.

Researchers at the Champalimaud Foundation in Lisbon have for the first time managed to identify with an imaging technique whether nervous impulses in the brain of rats are flowing in a “bottom-up” (feedforward), carrying information about visual input, or a “top-down” (feedback) direction, carrying information about expectations or predictions on a given task or about the perception of the world around us.

Groundbreaking research from the University of Houston shows that a single low-dose atropine eye drop can produce daylong effects in managing myopia.

A new study published in The Journal of Prevention of Alzheimer’s Disease suggests that these oral capsules may actually be linked to a faster decline in cognitive function.

Veppanu, the first PROTAC therapy approved by the FDA, improved progression free survival by 43% versus AstraZeneca’s Faslodex but showed no such significant benefit in the intention-to-treat analysis.

Indicated for people with Type 2 diabetes, the system would be Insulet’s first fully automated device for insulin delivery.

TaeWoong Medical, the fully covered, self-expanding metallic device, is intended to aid EUS drainage procedures.

https://medtechspectrum.com/news/40/25517/unm-scientist-studies-where-brain-cancer-cells-hide-and-how-to-fight-them.html

Scientists have developed a way to turn the body’s own immune cells into cancer-fighting agents—without removing them from the body—by using red blood cells to deliver genetic instructions.

A first-in-human clinical trial led by an international team of researchers and published in the New England Journal of Medicine found that setidegrasib, an investigational targeted therapy drug designed to eliminate a key cancer-driving protein called KRAS G12D, shows encouraging early activity in patients with advanced lung and pancreatic cancers.